Assessment and Prioritization of Attractive IO Targets
A global pharma company approached SmartAnalyst to evaluate the market and help it make strategic choices for acquiring its next immuno-oncology (IO) targets.
SmartAnalyst conducted secondary research and its depth of experience in IO to shortlist 25 targets for evaluation and prioritization, based on client-specific parameters, including biological rationale, scientific evidence, commercial considerations, and potential combinability of select targets with other novel IO targets.
SmartAnalyst identified the five most attractive IO targets through a close analysis of key indicators that helped the company to frame its strategic acquisitions.
Read the full case study here.
Jump to a slide with the slide dots.
Assessing the market for a novel gene therapy
Our client was preparing for the launch of a novel gene therapy and was looking to understand the potential value of its product in the market.
Read moreAssessing the commercial opportunity for a new CAR-T therapy
Read how we assessed the commercial opportunity for a new CAR-T therapy.
Read more